← Back to Compound Library IMMUNE

Thymosin Alpha-1

Thymosin Alpha-1 is a peptide that your thymus gland naturally produces to train and activate your immune system. It is one of the most extensively studied immune peptides in existence, with over 4,400 patients enrolled in clinical trials across the United States, Europe, and China. Your thymus is the organ behind your breastbone where T cells learn their job. T cells are critical for fighting infections and cancer. Thymosin Alpha-1 is the specific signal the thymus uses to mature these T cells and keep them working properly. Here is why this matters. A synthetic version of Thymosin Alpha-1 called thymalfasin (brand name Zadaxin) has been approved in over 35 countries for treating chronic hepatitis B, chronic hepatitis C, and as an adjunct therapy for certain cancers. It is used clinically to boost immune function in patients whose immune systems are compromised. What makes Thymosin Alpha-1 different from typical immune boosters is that it modulates rather than simply stimulates. If your immune system is suppressed, it brings it up. If your immune system is overactive (as in autoimmune conditions or severe inflammation), it helps calm it down. This balancing effect makes it useful across a wide range of conditions. Thymosin Alpha-1 is not FDA-approved in the United States, though it has orphan drug status for certain conditions. It is available as a research chemical.

How It Works

Thymosin Alpha-1 works through multiple pathways to enhance and balance your immune function.

Toll-Like Receptor Activation

Your immune cells have sensors called Toll-like receptors (TLRs) that detect threats. Thymosin Alpha-1 activates several of these sensors, including TLR-2 and TLR-9, which triggers your immune cells to mount a response. This is how it wakes up a sluggish immune system. By engaging these pattern-recognition receptors on dendritic cells and other antigen-presenting cells, Thymosin Alpha-1 initiates downstream signaling cascades that prime both innate and adaptive immune responses.

T Cell Enhancement

Thymosin Alpha-1 is particularly effective at boosting T cell function:

Increases CD4+ helper T cells, which are the coordinators that direct the immune

response

Increases CD8+ cytotoxic T cells, which are the killers that destroy infected cells
Helps immature T cells develop into fully functional ones through stimulation of

differentiation markers

Restores T cell function in individuals whose immunity has declined due to age, illness,

or immunosuppressive treatments

Natural Killer Cell Activation

Natural killer (NK) cells are first responders that kill virus-infected cells and tumor cells without needing prior exposure. Thymosin Alpha-1 directly activates these cells. In animal studies, it restored NK cell activity in immunosuppressed subjects, suggesting a role in reinforcing innate immune surveillance against both infections and malignancies.

Dendritic Cell Support

Dendritic cells are the teachers of your immune system. They capture threats and present them to T cells so they know what to attack. Thymosin Alpha-1 improves how effectively dendritic cells perform this function:

Stimulates dendritic cell maturation through TLR-dependent signaling
Promotes production of cytokines that drive Th1 immune responses, including

interleukin-12 and interferon-gamma

Cytokine Modulation

Thymosin Alpha-1 influences the production of multiple cytokines:

Increases IL-2 (T cell growth factor)
Increases IFN-gamma (antiviral and immune-activating cytokine)
Increases IL-1 beta, IL-3, and IL-6
Modulates TNF-alpha production
Increases IL-10 (anti-inflammatory cytokine), contributing to the immunomodulatory

rather than purely stimulatory profile

Antiviral Effects

Thymosin Alpha-1 exerts antiviral effects through two primary mechanisms: 1. Direct inhibition of viral replication and viral protein expression 2. Enhancement of immune function to eliminate infected cells It also increases expression of major histocompatibility complex (MHC) class I molecules on infected cells, making them more visible to cytotoxic T cells. This dual mechanism of direct antiviral action and immune enhancement is what makes Thymosin Alpha-1 particularly effective in chronic viral infections.

Benefits

Immune System Support

Thymosin Alpha-1 enhances overall immune function by:

Increasing T cell numbers and activity
Activating natural killer cells
Enhancing dendritic cell function
Improving antibody responses
Supporting the body’s ability to fight infections

Chronic Viral Infection Support

Thymosin Alpha-1 has been most extensively studied for chronic hepatitis B and C:

Multiple clinical trials demonstrate improved viral clearance rates
Enhanced response when combined with interferon therapy
Long-term follow-up studies show sustained responses
Better tolerated than interferon alone

Cancer Therapy Adjunct

Thymosin Alpha-1 has been studied as an adjunct to cancer therapy:

May help restore immune function suppressed by chemotherapy
Studied in melanoma, hepatocellular carcinoma, and non-small cell lung cancer
May enhance the body’s ability to recognize and fight tumor cells
Generally used alongside conventional cancer treatments, not as a standalone therapy

Vaccine Enhancement

Thymosin Alpha-1 can improve vaccine responses, particularly in:

Elderly individuals with weakened immune systems
Immunocompromised patients
Situations with limited antigen availability
Influenza and hepatitis B vaccination

Sepsis and Acute Infection

Thymosin Alpha-1 has been studied in severe sepsis:

May help restore immune function during severe infections
Studies during the COVID-19 pandemic showed potential benefits in patients with

lymphocytopenia

May reduce mortality in severe cases characterized by lymphocyte depletion

Anti-Inflammatory Effects

Despite its immune-enhancing properties, Thymosin Alpha-1 also has anti-inflammatory effects:

Reduces TNF-alpha and IL-1 beta in inflammatory conditions
May benefit chronic inflammatory conditions
Can help balance overactive immune responses through induction of regulatory T cells

and IDO (indoleamine 2,3-dioxygenase) activity

What the Science Shows

Thymosin Alpha-1 has extensive clinical research supporting its use in immune modulation.

Hepatitis B Studies

Mutchnick et al. (1991) conducted a placebo-controlled pilot trial in chronic hepatitis B patients. Results showed disease remission and cessation of virus replication, higher lymphocyte counts, increased IFN-gamma production, and sustained response at 2- to 5-year follow-up. Multiple subsequent trials confirmed Thymosin Alpha-1 effectiveness in hepatitis B, particularly in patients who are HBeAg-negative. Zhang et al. (2009) conducted a comprehensive meta-analysis evaluating the combination of lamivudine and Thymosin Alpha-1 in treating hepatitis B. The study included eight trials involving 583 patients. Results demonstrated that the combination yielded significant improvements in ALT normalization, virological response rate, and HBeAg seroconversion rate compared to lamivudine alone.

Immune Cell Enhancement

Li et al. (2003) studied Thymosin Alpha-1 in chronic hepatitis B patients. Results showed:

Significant increase in intrahepatic NKT cells
Increased CD8+ cytotoxic T lymphocytes in the liver
Decreased histology activity index scores, indicating reduced liver inflammation
Elevated immune cell levels that persisted through the end of treatment

Mechanism Studies

Romani et al. (2004, 2006, 2007) demonstrated the mechanism of action of Thymosin Alpha-1:

Confirmed TLR-2 and TLR-9 agonist activity
Showed activation of dendritic cells through TLR signaling pathways
Demonstrated induction of antifungal Th1 resistance through dendritic cell tryptophan

catabolism

Cancer Studies

Garaci et al. (2012) reviewed Thymosin Alpha-1’s action on immune effector cells and tumor target cells, demonstrating its potential as an adjunct in cancer immunotherapy. Maio et al. (2010) conducted a large randomized study of Thymosin Alpha-1 combined with interferon alfa and dacarbazine in patients with metastatic melanoma, showing improved progression-free survival without increased toxicity.

COVID-19 Research

Liu et al. (2020) studied Thymosin Alpha-1 in severe COVID-19 cases. Results showed:

Restoration of lymphocyte counts in patients with lymphocytopenia
Reversion of exhausted T cells to functional states
Potential mortality reduction in severe cases, though larger studies have shown mixed

results

Safety Profile

Over 4,400 subjects in clinical trials have demonstrated:

Well tolerated with only minor side effects
No significant adverse reactions in most studies
A sharp contrast to other immune modulators like interferon, which carry significant side

effect burdens

Dosing Protocol

Standard Protocol

Dose: 1.6 mg (1,600 mcg) subcutaneous injection Frequency: Twice weekly (commonly Monday and Thursday) Cycle Length: 4 to 12 weeks depending on application

By Application

Immune Support and Optimization:

1.6 mg twice weekly for 4 to 8 weeks
Can be used during cold and flu season
May repeat cycles with 4-week breaks between them

Chronic Infection Support:

1.6 mg twice weekly for 6 to 12 months (in clinical trials)
Often combined with other therapies such as interferon or antivirals
Duration depends on clinical response

Vaccine Enhancement:

1.6 mg twice weekly starting 2 weeks before vaccination
Continue for 2 to 4 weeks after vaccination

Cancer Adjunct Therapy:

1.6 mg twice weekly alongside conventional treatment
Duration matches the treatment course
Physician supervision required

Clinical Trial Dosing: Most clinical trials have used 1.6 mg twice weekly, which corresponds to the approved dosing of thymalfasin (Zadaxin) in countries where it is registered.

Administration

Thymosin Alpha-1 is administered via subcutaneous injection. It has good bioavailability when injected and reaches peak serum levels within approximately 2 hours.

Draw Volumes by Vial Size

10 mg Vial with 2 mL Bacteriostatic Water (5 mg/mL Concentration) Dose Volume Units on Syringe 800 mcg 0.16 mL 16 units 1,000 mcg 0.20 mL 20 units 1,600 mcg 0.32 mL 32 units 2,000 mcg 0.40 mL 40 units At 1.6 mg twice weekly, one 10 mg vial lasts approximately 3 weeks. 10 mg Vial with 1 mL Bacteriostatic Water (10 mg/mL Concentration) Dose Volume Units on Syringe 800 mcg 0.08 mL 8 units 1,000 mcg 0.10 mL 10 units 1,600 mcg 0.16 mL 16 units 2,000 mcg 0.20 mL 20 units This higher concentration allows smaller injection volumes.

Reconstitution

Materials Needed:

Thymosin Alpha-1 vial (lyophilized powder)
Bacteriostatic water
Sterile syringe for reconstitution
Alcohol swabs

Instructions: 1. Wipe the vial stopper and bacteriostatic water vial with alcohol swabs. 2. Draw 1 to 2 mL of bacteriostatic water (depending on desired concentration). 3. Insert the needle through the rubber stopper at an angle. 4. Let the water trickle slowly down the inside wall of the vial. 5. Do not inject directly onto the powder or shake vigorously. 6. Gently swirl until the powder is fully dissolved. 7. The solution should be clear. If it is cloudy or contains particles, do not use it. Thymosin Alpha-1 typically reconstitutes easily and produces a clear solution.

Side Effects

Thymosin Alpha-1 has an excellent safety profile across extensive clinical use. Common (Generally Mild):

Injection site reactions (redness, mild swelling)
Transient fatigue

Rare:

Erythema (skin redness)
Transient muscle atrophy at the injection site
Polyarthralgia (joint pain) combined with hand symptoms

Safety Comparison: The lack of significant side effects with Thymosin Alpha-1 contrasts sharply with other immune modulators. Unlike interferon, it does not cause flu-like symptoms, depression, or severe fatigue. Unlike other biologics, it does not carry a risk of serious immunosuppression or secondary infection. Thymosin Alpha-1 is generally very well tolerated even with long-term use. Clinical Trial Safety Data: Over 4,400 subjects in clinical trials have demonstrated favorable safety profiles. Thymosin Alpha-1 has been used safely in combination with interferon therapy, chemotherapy, and various vaccines.

Contraindications and Precautions

Do Not Use If:

You have a known hypersensitivity to Thymosin Alpha-1 or any component of the

formulation

You are currently taking immunosuppressant medications deliberately (such as organ

transplant recipients) Use Caution With:

Pregnancy or breastfeeding (safety has not been established)
Autoimmune conditions (consult a physician first)
Pediatric use (safety has not been established in children)

Drug Interactions: Thymosin Alpha-1 has been safely combined with many treatments in clinical trials, including interferon alpha, ribavirin, chemotherapy agents, and vaccines. However, it should not be used in patients who are deliberately immunosuppressed, such as transplant recipients on immunosuppressant medications. Consult a qualified healthcare provider before use.

Comparison

Compound Mechanism Best For Thymosin Alpha-1 TLR activation, T cell Chronic infection support, enhancement, NK cell activation immune optimization, vaccine enhancement Thymalin Thymic extract containing General immune support, age- multiple thymic factors related immune decline BPC-157 Growth factors, angiogenesis Tissue healing, injury recovery KPV NF-kB inhibition, cytokine Anti-inflammatory support, gut suppression inflammation

Thymosin Alpha-1 vs. Thymalin

Both are thymic peptides but differ significantly in composition. Thymosin Alpha-1 is a single, well-characterized 28-amino-acid peptide with a defined molecular weight of 3,108 Da. Thymalin is a thymic extract containing multiple thymic factors. Thymosin Alpha-1 has considerably more extensive clinical trial data and a more precisely understood mechanism of action. Both support immune function through thymic mechanisms, but Thymosin Alpha-1 offers greater consistency and reproducibility in research and clinical settings.

Success Tips

Timing for Immune Support

Consider using Thymosin Alpha-1:

Before and during cold and flu season
Before travel to areas with infectious disease risk
When the immune system may be compromised
As part of recovery from illness

Combine with Good Immune Fundamentals

Thymosin Alpha-1 works best alongside:

Adequate sleep (7 to 9 hours per night)
Stress management
Balanced nutrition with adequate protein
Regular moderate exercise
Vitamin D optimization

For Vaccine Enhancement

If using Thymosin Alpha-1 to enhance vaccine response:

Start 2 weeks before vaccination
Continue for 2 to 4 weeks after vaccination
Particularly useful for elderly or immunocompromised individuals

Monitor Your Response

Pay attention to:

Frequency of infections
Duration of illness when sick
Energy levels
Overall sense of well-being

Storage and Handling

Before Reconstitution:

Store lyophilized (powder) vials in the refrigerator at 36 to 46 degrees Fahrenheit (2 to 8

degrees Celsius)

Can be stored at room temperature for short periods
Protect from light

After Reconstitution:

Refrigerate at 36 to 46 degrees Fahrenheit
Use within 4 weeks when reconstituted with bacteriostatic water
Do not freeze after reconstitution
Keep the stopper clean
If the solution becomes cloudy or contains particles, discard it

Legal Status

United States: Thymosin Alpha-1 is not FDA-approved for general use. It has orphan drug designation for:

Malignant melanoma
Chronic active hepatitis B
DiGeorge anomaly with immune defects
Hepatocellular carcinoma

It is available as a research chemical. International: Thymalfasin (Zadaxin) is approved in over 35 countries for:

Chronic hepatitis B
Chronic hepatitis C
Immune enhancement
Cancer adjunct therapy

Product Source

Thymosin Alpha-1 is available for research purposes from Peptide Sciences. When sourcing research-grade Thymosin Alpha-1, ensure the supplier provides third-party testing, certificates of analysis (COA), and proper documentation of purity (typically ≥98%). Always verify the legitimacy and quality standards of any peptide supplier.

Frequently Asked Questions

How is Thymosin Alpha-1 different from other immune boosters? Most immune boosters simply stimulate the immune system. Thymosin Alpha-1 is an immunomodulator, meaning it can enhance suppressed immune function while also helping regulate overactive responses. This bidirectional activity makes it useful for a wider range of conditions and generally safer than simple immune stimulants. How long until I notice effects? Immune system changes may not produce obvious symptoms. Clinical markers typically improve within 2 to 4 weeks. A reduced frequency of infections or faster recovery from illness may be noticed over 4 to 8 weeks of use. Can I use Thymosin Alpha-1 if I have an autoimmune condition? Thymosin Alpha-1 has immunomodulatory rather than purely stimulatory effects, and some research suggests it may help balance immune responses. However, autoimmune conditions are complex. Consult your physician before using Thymosin Alpha-1 if you have an autoimmune condition. Is Thymosin Alpha-1 the same as Thymalin? No. Thymosin Alpha-1 is a single, well-characterized 28-amino-acid peptide with a molecular weight of 3,108 Da. Thymalin is a thymic extract containing multiple factors. Both support immune function, but through somewhat different compositions and mechanisms. Can Thymosin Alpha-1 be combined with other peptides? Thymosin Alpha-1 has been safely combined with many treatments in clinical settings. It may complement other health-supporting peptides. However, specific combinations should be discussed with a healthcare provider.

References

1. Tuthill C, Rios I, McBeath R. Immune Modulation with Thymosin Alpha 1 Treatment. Vitam Horm. 2016;102:151-178. https://pubmed.ncbi.nlm.nih.gov/27450734/ 2. Dominari A, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67-78. https://pubmed.ncbi.nlm.nih.gov/33362999/ 3. Tao N, et al. Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Molecules. 2023;28(8):3539. https://pubmed.ncbi.nlm.nih.gov/37110771/ 4. Li Y, et al. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Clin Exp Med. 2003;3(1):1-10. https://pubmed.ncbi.nlm.nih.gov/12479932/ 5. Garaci E, et al. Thymosin alpha 1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci. 2012;1269:26-33. https://pubmed.ncbi.nlm.nih.gov/23045967/ 6. Romani L, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103(11):4232-4239. 7. Maio M, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol. 2010;28(10):1780-1787. https://pubmed.ncbi.nlm.nih.gov/20195296/ 8. Zhang Y, et al. Treatment of hepatitis B virus infection with lamivudine versus lamivudine and thymosin alpha-1: a meta-analysis. Virol J. 2009;6:63.